BRPI0907976A2 - Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças - Google Patents

Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Info

Publication number
BRPI0907976A2
BRPI0907976A2 BRPI0907976-9A BRPI0907976A BRPI0907976A2 BR PI0907976 A2 BRPI0907976 A2 BR PI0907976A2 BR PI0907976 A BRPI0907976 A BR PI0907976A BR PI0907976 A2 BRPI0907976 A2 BR PI0907976A2
Authority
BR
Brazil
Prior art keywords
compound
treating
pharmaceutical composition
preventing disease
disease
Prior art date
Application number
BRPI0907976-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Angelo Guglielmotti
Guido Furlotti
Giorgina Mangano
Nicola Cazzolla
Barbara Garofalo
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of BRPI0907976A2 publication Critical patent/BRPI0907976A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
BRPI0907976-9A 2008-03-07 2009-03-05 Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças BRPI0907976A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07
PCT/EP2009/052585 WO2009109613A2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40

Publications (1)

Publication Number Publication Date
BRPI0907976A2 true BRPI0907976A2 (pt) 2015-08-04

Family

ID=39671487

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0907976-9A BRPI0907976A2 (pt) 2008-03-07 2009-03-05 Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0907977-7A BRPI0907977A2 (pt) 2008-03-07 2009-03-05 Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0907977-7A BRPI0907977A2 (pt) 2008-03-07 2009-03-05 Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Country Status (25)

Country Link
US (3) US8835481B2 (enExample)
EP (3) EP2254869B1 (enExample)
JP (2) JP5509101B2 (enExample)
KR (2) KR101581828B1 (enExample)
CN (2) CN101945855B (enExample)
AR (2) AR070810A1 (enExample)
AU (2) AU2009221083B2 (enExample)
BR (2) BRPI0907976A2 (enExample)
CA (2) CA2712403C (enExample)
CY (2) CY1117584T1 (enExample)
DK (2) DK2254869T3 (enExample)
EA (2) EA019711B1 (enExample)
ES (2) ES2637009T3 (enExample)
GE (2) GEP20135983B (enExample)
HR (2) HRP20171208T1 (enExample)
HU (1) HUE027098T2 (enExample)
IL (3) IL206893A0 (enExample)
LT (1) LT2254869T (enExample)
MX (2) MX2010009626A (enExample)
PL (2) PL2254869T3 (enExample)
PT (1) PT2254869T (enExample)
SG (1) SG188177A1 (enExample)
SI (2) SI2254869T1 (enExample)
UA (2) UA105170C2 (enExample)
WO (2) WO2009109618A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109616A2 (en) * 2008-03-07 2009-09-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
PT2254869T (pt) * 2008-03-07 2017-07-18 Acraf Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40
CN101959866B (zh) 2008-03-07 2013-10-02 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途
CN102471282A (zh) * 2009-08-03 2012-05-23 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟甲基-1h-吲唑及其衍生物以及所需镁中间体的制备方法
UA108742C2 (uk) 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
EP3338776A1 (en) * 2012-05-01 2018-06-27 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US8999292B2 (en) * 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
ES2612205T3 (es) 2012-05-18 2017-05-12 Sanofi Derivados de pirazol y su uso como antagonistas de LPAR5
US9346757B2 (en) 2012-05-18 2016-05-24 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
AU2013342209B2 (en) 2012-11-09 2016-05-26 Colgate-Palmolive Company Block copolymers for tooth enamel protection
WO2015173786A1 (en) * 2014-05-15 2015-11-19 Boyd Shelley Romayne Compositions and methods for treating and diagnosing ocular disorders
EP3942934A1 (en) * 2015-06-12 2022-01-26 Vettore, LLC Mct4 inhibitors for treating disease
WO2016203313A1 (en) * 2015-06-16 2016-12-22 Translatum Medicus, Inc. Compositions and methods for treating and diagnosing ocular disorders
CA3046212A1 (en) 2016-12-12 2018-06-21 Vettore, LLC Heterocyclic inhibitors of mct4
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
CA3144861A1 (en) 2019-06-25 2020-12-30 Translatum Medicus, Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法
WO2024108386A1 (zh) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
WO2024165925A1 (en) * 2023-02-10 2024-08-15 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US364371A (en) * 1887-06-07 peice
US416359A (en) * 1889-12-03 Sash-fastener
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
WO2000078757A1 (en) 1999-06-17 2000-12-28 Shionogi Bioresearch Corp. Inhibitors of il-12 production
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
ATE417617T1 (de) 2001-03-15 2009-01-15 Seikagaku Kogyo Co Ltd Mittel zur steurung der expression von il-12
CA2468349A1 (en) 2001-11-30 2003-06-12 Synta Pharmaceuticals Corporation Pyrimidine compounds
MXPA06003792A (es) 2003-10-07 2006-06-14 Astrazeneca Ab Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1.
WO2006046739A1 (ja) * 2004-10-29 2006-05-04 Eisai R & D Management Co., Ltd. 炎症性疾患治療剤
EP1819341A4 (en) 2004-11-10 2011-06-29 Synta Pharmaceuticals Corp IL-12 MODULATORY CONNECTIONS
WO2006060194A1 (en) 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
WO2009109616A2 (en) 2008-03-07 2009-09-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Novel 1-benzil-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
CN101959866B (zh) 2008-03-07 2013-10-02 方济各安吉利克化学联合股份有限公司 1-苄基-3-羟基甲基吲唑衍生物及其在治疗基于mcp-1和cx3cr1表达的疾病中的用途
PT2254869T (pt) 2008-03-07 2017-07-18 Acraf Novos derivados de 1-benzil-3-hidroximetilindazole e suas utilizações no tratamento de doenças com base na expressão de cx3cr1 e p40

Also Published As

Publication number Publication date
IL207131A0 (en) 2010-12-30
MX2010009626A (es) 2010-12-20
JP5509099B2 (ja) 2014-06-04
GEP20135912B (en) 2013-08-26
CN101952256A (zh) 2011-01-19
JP5509101B2 (ja) 2014-06-04
PT2254869T (pt) 2017-07-18
AU2009221089A1 (en) 2009-09-11
JP2011513367A (ja) 2011-04-28
DK2254870T3 (en) 2016-05-17
JP2011513365A (ja) 2011-04-28
ES2569330T3 (es) 2016-05-10
EP2254870A2 (en) 2010-12-01
CA2712403C (en) 2017-06-06
SG188177A1 (en) 2013-03-28
PL2254870T3 (pl) 2016-07-29
SI2254869T1 (sl) 2017-10-30
EA018241B1 (ru) 2013-06-28
CN101945855B (zh) 2014-12-17
EA201071038A1 (ru) 2011-02-28
US20110003874A1 (en) 2011-01-06
PL2254869T3 (pl) 2017-10-31
LT2254869T (lt) 2017-08-10
IL215579A (en) 2015-06-30
MX2010009623A (es) 2010-09-28
ES2637009T3 (es) 2017-10-10
HRP20171208T1 (hr) 2017-10-06
AR070810A1 (es) 2010-05-05
AR070811A1 (es) 2010-05-05
DK2254869T3 (en) 2017-09-04
CA2712403A1 (en) 2009-09-11
US7919518B2 (en) 2011-04-05
GEP20135983B (en) 2013-12-10
WO2009109613A3 (en) 2009-12-10
UA103605C2 (en) 2013-11-11
WO2009109613A2 (en) 2009-09-11
US8283348B2 (en) 2012-10-09
HUE027098T2 (en) 2016-08-29
CN101945855A (zh) 2011-01-12
CN101952256B (zh) 2016-03-16
CY1117584T1 (el) 2017-04-26
EP3181551A1 (en) 2017-06-21
BRPI0907977A2 (pt) 2015-08-04
EP2254869A2 (en) 2010-12-01
IL206893A0 (en) 2010-12-30
SI2254870T1 (sl) 2016-05-31
UA105170C2 (en) 2014-04-25
US20110160205A1 (en) 2011-06-30
WO2009109618A2 (en) 2009-09-11
CA2712703C (en) 2016-10-11
EA201071040A1 (ru) 2011-02-28
CY1119252T1 (el) 2018-02-14
IL215579A0 (en) 2011-11-30
WO2009109618A3 (en) 2009-12-10
US8835481B2 (en) 2014-09-16
IL207131A (en) 2013-02-28
CA2712703A1 (en) 2009-09-11
AU2009221083B2 (en) 2013-11-28
KR101581828B1 (ko) 2015-12-31
AU2009221089B2 (en) 2013-12-05
HRP20160462T1 (hr) 2016-06-03
EP2254869B1 (en) 2017-05-31
KR20100131432A (ko) 2010-12-15
KR101599867B1 (ko) 2016-03-04
EA019711B1 (ru) 2014-05-30
AU2009221083A1 (en) 2009-09-11
EP2254870B1 (en) 2016-02-24
KR20100133957A (ko) 2010-12-22
US20100311744A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0907976A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0907974A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0912348A2 (pt) composto de 3-aminocarbazol, composição farmacêutica, método para preparar um composto de 3-aminocarbazol, uso de um composto de 3-aminocarbazol, e, método para tratar ou prevenir doenças
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0917705A2 (pt) composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto
BRPI0819799A2 (pt) Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0908883A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI1008383A2 (pt) composto, composição farmacêutica, método para prevenir, inibir ou tratar uma condição, e, uso de um composto
BRPI0911685A2 (pt) composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0819755A2 (pt) composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0815591A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BR122020011920A2 (pt) composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0917138A2 (pt) composto, métodos para tratar doenças alérgicas e outras condições inflamatórias, rinite alérgica, e para tratar ou prevenir doença, composição farmacêutica, uso de um composto, e, combinação.
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BRPI0917013A2 (pt) métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
BRPI0906786A2 (pt) Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0909768A2 (pt) composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0821299A2 (pt) Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0820568A2 (pt) Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2504 DE 02-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.